Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
37 hedge funds and large institutions have $27.3M invested in Carisma Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 11 closing their positions.
713% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $240K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.28% less ownership
Funds ownership: 1.43% → 1.15% (-0.28%)
14% less funds holding
Funds holding: 43 → 37 (-6)
37% less capital invested
Capital invested by funds: $43.6M → $27.3M (-$16.2M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$328K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$204K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$184K |
| 4 |
BlackRock
New York
|
+$83.2K |
| 5 |
MTIM
Marathon Trading Investment Management
Radnor,
Pennsylvania
|
+$58.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.95M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.96M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.88M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$300K |
| 5 |
VF
Virtu Financial
New York
|
-$194K |
CARM Hedge Fund Activity: Q3 2019 in Review
37 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2019, worth a combined $27.3M — down 37% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CARM and 5 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $328K. The largest seller was CVI Holdings, cutting an estimated $3.95M.
- 37 institutional investors held Carisma Therapeutics (CARM) as of Q3 2019, down from 43 in Q2 2019.
- Funds reported $27.3M of Carisma Therapeutics stock for Q3 2019, down 37% quarter-over-quarter.
- 5 funds opened new Carisma Therapeutics positions in Q3 2019 and 11 closed out, a net change of -6 holders.
- The largest Carisma Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $328K added.
- The largest Carisma Therapeutics seller in Q3 2019 was CVI Holdings, an estimated $3.95M sold.
Based on aggregated 13F filings for Q3 2019.